F. Shen

Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial

Guizhen Wu, Jin Zhang, W. Lei, 2022, Signal Transduction and Targeted Therapy.

A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants

Weijin Huang, Zhaofeng Liu, Jin Zhang, 2022, bioRxiv.

Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial

Guizhen Wu, Zhixin Ma, Shi Chen, 2023, Signal Transduction and Targeted Therapy.

Design of a mutation-integrated trimeric RBD with broad protection against SARS-CoV-2

Zhixin Ma, Shi Chen, Zhong-yu Hu, 2022, Cell Discovery.

Design of a mutation-integrated trimeric RBD with broad protection against SARS-CoV-2

Zhixin Ma, Shi Chen, Zhong-yu Hu, 2022, Cell discovery.

Structure and computation-guided design of a mutation-integrated trimeric RBD candidate vaccine with broad neutralization against SARS-CoV-2

Wei-min Zhou, Zhixin Ma, Wei Huang, 2021, bioRxiv.